🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesHas anyone dealt with surpass-cvot: tirzepatide cardiovascular outcomes trial design? Page 3

Has anyone dealt with surpass-cvot: tirzepatide cardiovascular outcomes trial design?

lori_vegas Tue, Nov 12, 2024 at 6:39 AM 11 replies 1,688 viewsPage 3 of 3
HPLC_Greg
Senior Member
1,890
8,901
Feb 2024
Research Triangle, NC
Nov 13, 2024 at 8:13 AM#11
hyun_seoul said:
SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

Agreed, with the qualification that SELECT enrolled a secondary-prevention population. Extrapolating a 20% relative reduction to a healthy 35-year-old with a BMI of 31 is not what that trial showed.

Worth separating that from cardiovascular outcomes, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Last edited: Nov 13, 2024 at 2:13 PM
39 12SallyK_inj, CryptoCarl, MariaRD and 36 others
Reply Quote Save Share Report
JenPlateau
Member
234
890
Nov 2024
Missouri
Nov 13, 2024 at 10:38 AM#12
Dr.EndoIndy said:
True, though the ladder is longer and that is not a neutral detail — six dose steps means six opportunities to stall on the way up, and plenty of…

This answered a question I did not know how to ask. Sending this to two other people who asked me the same thing last week.

Last edited: Nov 13, 2024 at 4:38 PM
40 13TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 37 others
Reply Quote Save Share Report
bri_stats
Member
789
3,456
May 2024
Seattle, WA
Nov 13, 2024 at 1:03 PM#13
hyun_seoul said:
SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

Pushing back on hyun_seoul here. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

Worth separating that from cardiovascular outcomes, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

41 14TomFromTexas, mike.trainer_LA, sarah_nash92 and 38 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
Nov 13, 2024 at 3:28 PM#14

The figures, for anyone assembling their own picture. The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the same conditions. Nobody wants that answer and it is still the answer.

Last edited: Nov 13, 2024 at 4:28 PM
42 15Dr.BariatricHTX, LindaRN_retired, tommy_boulder and 39 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Nov 13, 2024 at 5:53 PM#15

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here.

43 16PurityPaulOR, MaxMetOK, MounjBrad and 40 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register